MTHFD2

Across TCGA pan-cancer cohorts, MTHFD2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTHFD2 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTHFD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFD2 expression acts as an unfavorable survival marker.

LUAD, COAD, and SARC are the cancer types where MTHFD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.266	0.835	<.001	18	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
SARC	OS	Median	All	0.250	0.766	.030	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTHFD2–LUAD (OS)

Open the LUAD breakdown →